Home › Compare › RAFA vs EQR

RAFA vs EQR: Dividend Comparison 2026

RAFA yields 3030.30% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RAFA wins by $500360607186.77M in total portfolio value
10 years
RAFA
RAFA
● Live price
3030.30%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$500360607186.81M
Annual income
$469,859,227,990,298,900.00
Full RAFA calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — RAFA vs EQR

📍 RAFA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRAFAEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RAFA + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
RAFA pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RAFA
Annual income on $10K today (after 15% tax)
$257,575.76/yr
After 10yr DRIP, annual income (after tax)
$399,380,343,791,754,050.00/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, RAFA beats the other by $399,380,343,791,750,800.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RAFA + EQR for your $10,000?

RAFA: 50%EQR: 50%
100% EQR50/50100% RAFA
Portfolio after 10yr
$250180303593.43M
Annual income
$234,929,613,995,151,360.00/yr
Blended yield
93.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

RAFA
No analyst data
Altman Z
3.1
Piotroski
4/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RAFA buys
0
EQR buys
0
No recent congressional trades found for RAFA or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRAFAEQR
Forward yield3030.30% ✓4.73%
Annual dividend / share$2.00$2.77 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$500360607186.81M ✓$40.5K
Annual income after 10y$469,859,227,990,298,900.00 ✓$3,819.61
Total dividends collected$498252908594.85M ✓$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: RAFA vs EQR ($10,000, DRIP)

YearRAFA PortfolioRAFA Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$313,730$303,030.30$11,248$547.57+$302.5K → RAFA
2$9,220,718$8,885,026.99$12,701$666.53+$9.21M → RAFA
3$253,918,671$244,052,501.99$14,405$814.59+$253.90M → RAFA
4$6,552,701,214$6,281,008,236.19$16,413$999.84+$6552.68M → RAFA
5$158,496,977,633$151,485,587,333.73$18,795$1,232.92+$158496.96M → RAFA
6$3,594,020,691,580$3,424,428,925,512.90$21,639$1,527.95+$3594020.67M → RAFA
7$76,416,745,778,469$72,571,143,638,478.27$25,057$1,903.80+$76416745.75M → RAFA
8$1,523,841,939,473,922$1,442,076,021,490,960.80$29,197$2,385.87+$1523841939.44M → RAFA
9$28,505,961,865,899,772$26,875,450,990,662,680.00$34,250$3,008.70+$28505961865.87M → RAFA
10$500,360,607,186,811,600$469,859,227,990,298,900.00$40,467$3,819.61+$500360607186.77M → RAFA

RAFA vs EQR: Complete Analysis 2026

RAFA — Stock

Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. It offers cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules. The company also provides drugs for accidental wounds, inflammatory eye diseases, and immunological disorders. The company has a collaboration agreement with PlantEXT Ltd. to research and manufacture the first medical cannabis suppositories for patients suffering from inflammatory bowel disease. Rafarma Pharmaceuticals, Inc. was formerly known as Johnston Acquisition Corp. and changed its name to Rafarma Pharmaceuticals, Inc. in October 2012. The company is based in Sandy, Utah with a manufacturing and distribution facility in Russia. As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.

Full RAFA Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this RAFA vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RAFA vs SCHDRAFA vs JEPIRAFA vs ORAFA vs KORAFA vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.